Tailor Bio
↗Cambridge, United Kingdom
Tailor Bio is a precision oncology company spun out of the Cancer Research UK (CRUK) Cambridge Institute. The company is developing a pan-cancer precision medicine platform focused on chromosomal instability (CIN), a genomic hallmark present in approximately 80% of all cancers. By utilizing proprietary AI algorithms to decode complex CIN signatures, Tailor Bio aims to predict patient response to existing chemotherapies and identify novel therapeutic targets.
The company's platform enables the simultaneous development of drug discovery programs and companion diagnostics. Their technology is designed to transform the treatment landscape for aggressive, difficult-to-treat cancers by turning genomic 'chaos' into actionable therapeutic opportunities. Tailor Bio is currently advancing its lead diagnostic test through analytical validation while building a pipeline of small molecule inhibitors targeting CIN-driven vulnerabilities.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M-$1M
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$2.71M
Investors:Acequia Capital, Ascension, Illumina, First In Ventures, Time Partners, Innovate UK, Cambridgeshire and Peterborough Combined Authority
PIPELINE
Stage:Preclinical
Lead Drug Stage:Diagnostic Validation / Preclinical
Modalities:Diagnostics, Biomarkers, Small molecule, AI-driven target discovery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Volastra Therapeutics (KIF18A inhibitor biomarker collaboration), University of Cambridge, Spanish National Cancer Research Centre (CNIO), Cancer Research UK (CRUK)
COMPETITION
Position:Emerging
Competitors:Volastra Therapeutics, Repare Therapeutics, Artios Pharma, Tango Therapeutics
LEADERSHIP
Key Executives:
Jason Yip - CEO & Co-Founder
Geoff Macintyre - CSO & Co-Founder
Nicola Wallis - Head of Drug Discovery
Scientific Founders:Jason Yip, Geoff Macintyre, Ania Piskorz, Florian Markowetz, James Brenton
Board Members:Hitesh Sanganee (Independent NED, ex-AstraZeneca), Kathryn Corzo (Independent NED, President of Bit.bio), Özgür Tuncer (Investor Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Tailor Bio. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.